Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Mentice publishes the company’s interim report for the period January–March 2020

Thursday, May 14, 2020

Encouraging signs for the medium to long-term outlook, while the uncertainty in 2020 remains
 

First quarter 2020

  • Net sales amounted to 33.8 (27.5) MSEK.
  • Operating result for the period before depreciations (EBITDA) totalled -0.5 (-7.9) MSEK.
  • Net result for the period amounted to -5.0 (-8.5) MSEK.
  • Earnings per share (EPS) was -0.21 (-0.76) SEK.
  • Order intake amounted to 32.5 (25.1) MSEK.
  • Cash flow from operating activities totalled 1.5 (-3.7) MSEK.

“In the first quarter, we managed to regain some of the projects that did not materialise in 2019. This contributed to Q1 2020 order intake figures coming in substantially above the same period last year in both our medical device industry segment (+84 %) and in strategic alliances (+160 %), while our healthcare systems segment was negatively impacted by the Covid-19 situation. Overall, we are pleased to report a net sales increase of 23 % and a 30 % increase in orders received compared to the first quarter of 2019. We are also pleased to see that our cost-reducing measures combined with stronger sales has moved us to a just slightly negative operating profit of -0.5 MSEK compared to

-7.9 MSEK for the same period last year,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for January–March 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on May 14, 2020 at 10:00 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations.

Please make sure to register at least a few minutes in advance.

 

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on May 14, 2020 08:30 CET.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Mentice publishes the company’s interim report for the period January–March 2020

Thursday, May 14, 2020

Encouraging signs for the medium to long-term outlook, while the uncertainty in 2020 remains
 

First quarter 2020

  • Net sales amounted to 33.8 (27.5) MSEK.
  • Operating result for the period before depreciations (EBITDA) totalled -0.5 (-7.9) MSEK.
  • Net result for the period amounted to -5.0 (-8.5) MSEK.
  • Earnings per share (EPS) was -0.21 (-0.76) SEK.
  • Order intake amounted to 32.5 (25.1) MSEK.
  • Cash flow from operating activities totalled 1.5 (-3.7) MSEK.

“In the first quarter, we managed to regain some of the projects that did not materialise in 2019. This contributed to Q1 2020 order intake figures coming in substantially above the same period last year in both our medical device industry segment (+84 %) and in strategic alliances (+160 %), while our healthcare systems segment was negatively impacted by the Covid-19 situation. Overall, we are pleased to report a net sales increase of 23 % and a 30 % increase in orders received compared to the first quarter of 2019. We are also pleased to see that our cost-reducing measures combined with stronger sales has moved us to a just slightly negative operating profit of -0.5 MSEK compared to

-7.9 MSEK for the same period last year,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for January–March 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on May 14, 2020 at 10:00 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations.

Please make sure to register at least a few minutes in advance.

 

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on May 14, 2020 08:30 CET.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.